Finanzen von Artiva Biotherapeutics Inc (ARTV)ARTVArtiva Biotherapeutics Inc

Evaluating the bottom line, Artiva Biotherapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -36.58%, provide a clear picture of how effectively ARTV converts its operational activities into shareholder value.

In the context of the broader market, ARTV competes directly with industry leaders such as NAGE and USNA. With a market capitalization of $559.79M, it holds a leading position in the sector. When comparing efficiency, ARTV's gross margin of N/A stands against NAGE's 64.84% and USNA's 78.35%. Such benchmarking helps identify whether Artiva Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

Artiva has reported consistent net losses, with Q1 2026 showing a loss of $23.5 million and an EPS of -$0.95. However, it maintains a strong cash position of $86.8 million, which is expected to fund operations into Q2 2027.